Crystal forms of β-nicotinamide mononucleotide
The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.
1. A crystalline form of a compound having the structure of formula (I),
wherein the crystalline form is a dimethylsulfoxide solvate.
2. The crystalline form of claim 1 , wherein the crystalline form is Form 2 having 2θ values 8.29; 17.39; 19.54; 22.78; and 22.98.
3. The crystalline form of claim 1 , having 2θ values 8.29; 17.39; 19.54; 19.74; 20.98; 21.58; 22.03; 22.78; 22.98; and 25.53.
4. The crystalline form of claim 3 , having 2θ values 8.29; 16.10; 17.39; 19.24; 19.54; 19.74; 20.33; 20.78; 20.98; 21.18; 21.58; 22.03; 22.78; 22.98; 25.53; 28.48; and 29.48.
5. The crystalline form of claim 4 , having 2θ values 8.29; 13.12; 15.79; 16.10; 16.69; 17.39; 19.03; 19.24; 19.54; 19.74; 20.33; 20.78; 20.98; 21.18; 21.58; 22.03; 22.78; 22.98; 23.95; 24.14; 24.48; 24.64; 25.14; 25.53; 25.87; 26.89; 27.18; 27.67; 28.02; 28.13; 28.48; 28.98; 29.34; 29.48; and 29.92.
6. The crystalline form of claim 5 , having an XRD pattern substantially as shown in FIG. 1 , labeled Form 2.
7. A pharmaceutical composition comprising the crystalline form of any one of claims 1 - 6 and one or more pharmaceutically acceptable excipients.
8. A method for preparing a crystalline form of the compound having the structure of formula (I):
comprising:
a) providing a mixture of a compound of formula (I) in a solvent; and
b) crystallizing the compound of formula (I) from the mixture comprising the compound of formula (I) wherein the crystalline form is a solvate.
9. The method of claim 8 , wherein the solvate is a dimethylsulfoxide solvate.
10. The method of claim 9 , wherein the solvent is dimethylsulfoxide.
11. The method of claim 8 , wherein the mixture comprising the compound of formula (I) is a solution, and the step of crystallizing the compound of formula (I) from the mixture comprises bringing the solution to supersaturation to cause the compound of formula (I) to precipitate out of solution.
12. The method of claim 11 , wherein the step of bringing the solution to supersaturation comprises slowly adding an anti-solvent, allowing the solution to cool, reducing the volume of the solution, or any combination thereof.
13. The method of claim 11 , wherein the step of bringing the solution to supersaturation comprises cooling the solution to ambient temperature or lower.
14. The method of claim 8 , wherein the mixture comprising the compound of formula (I) is a slurry.
15. The method of claim 8 , further comprising isolating the crystalline form of the compound.
16. The method of claim 15 , wherein isolating the crystalline form of the compound comprises filtering the crystalline compound from the mixture.
17. The method of claim 15 , further comprising drying the crystalline form of the compound under reduced pressure.